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KAM=0.12 and 0.05%Nm/BW.HT respectively). Function did not improve
signiﬁcantly following quadriceps strengthening in either alignment group
but there was a signiﬁcant improvement in knee pain in the more neutral
group only (P< 0.001).
Conclusions: Quadriceps strengthening did not have any signiﬁcant
effect on the KAM in participants with either more varus or more neutral
alignment. The beneﬁts of quadriceps strengthening on pain were more
evident in those with more neutral alignment. Knee alignment thus repre-
sents a local mechanical factor that can mediate symptomatic outcome
from exercise interventions in knee OA.
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Purpose: Curcumin is the principal biologically active component of
turmeric (Curcuma longa). Although it has been extensively investigated
for its anti-tumor, antioxidant and anti-inﬂammatory properties in various
cell models, few studies have explored its potential for counteracting
inﬂammatory and catabolic pathways in articular cartilage. Curcumin
has been shown to suppress the NFúB pathway and protect isolated
human chondrocytes from the catabolic effects of Il-1b. The aim of this
study was to see if curcumin could reduce glycosaminoglycan (GAG)
and prostaglandin E2 (PGE2) release from explants of equine articular
cartilage incubated with recombinant equine Il-1b in an in vitro model of
inﬂammatory OA.
Methods: Normal articular cartilage was obtained from weight bearing
regions of the metacarpophalangeal joints of three horses euthanized
for purposes other than for research. Cartilage explants were incubated
with 10 ng/ml equine recombinant Il-1b and curcumin at 25 mM, 50mM,
75mM or 100mM at 37ºC for 5 days in serum free DMEM. The dimethyl-
methylene blue (DMMB) assay was used to measure GAG release and
PGE2 immunoassays were used to assess the potential anti-inﬂammatory
effects of curcumin. Results were statistically analyzed using a one way
ANOVA with a Newman-Keuls post hoc test. Statistical signiﬁcance was
set at P <0.05.
Results: Curcumin signiﬁcantly reduced Il-1b-stimulated GAG release in
the explants at 50mM (P <0.05), 75mM (P < 0.01) and 100mM (P < 0.001).
PGE2 release in response to Il-1b exposure was diminished by curcumin
at 25mM, 50mM, 75mM and 100mM (P < 0.001).
Conclusions: This study demonstrates that micromolar concentrations
of curcumin exert signiﬁcant anti-catabolic and anti-inﬂammatory effects
in our inﬂammatory model of OA. These results support the use of
this cartilage explant model as a screening assay for novel functional
ingredients.
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Purpose: The degenerative joint disease, osteoarthritis (OA), is char-
acterised with a loss of cartilage and increased pain from affected
joints. It is this chronic pain which most patients associate with their
condition. Non-steroidal anti-inﬂammatory drugs (NSAIDs) are used to
treat inﬂammation and as a knock on effect, through the reduction of
COX2 and prostaglandin E2 (PGE2), can reduce the pain associated
with OA. However, NSAIDs are generally administered systemically and
can exhibit harmful side effects. Hyaluronans have also been shown to
reduce the pain associated with OA both in animal models and in clinical
trials. Applied locally hyaluronans target the disease in the affected limb,
further more the frequency of side effects of hyaluronans is considered
to be low and are generally not serious in nature. There are a number of
puriﬁed hyaluronans available and in recent years hyaluronan hydrogels,
where the material has been crosslinked into networks, have become
available. One of these crosslinked hyaluronan hydrogels is DurolaneTM.
This study has sought to evaluate the effect of Durolane in an in vivo
model of joint pain.
Methods: The model utilized the pain inducing substances bradykinin &
PGE2 administered intra-articular (IA) and unilaterally into the knee joints
of adult female Lewis rats. Rats were randomly allocated to one of
three groups, Durolane, saline or morphine. The saline and Durolane
(20mg/ml) groups were injected IA (50 ul) once (Day 1), 2−4 hours before
the ﬁrst injection of bradykinin (182.25mg) and PGE2 (0.5mg) into the rat
knee. The administration of the pain inducing agents was approximately
45 minutes before initiation of behavioural testing on each testing day. The
morphine acted as a positive control and was administered at 2.5mg/kg
subcutaneously 30 minutes after bradykinin/PGE2 on each testing day.
Behavioural testing was performed at 2 hours and 1, 2, 4, 7, 14, 21 and
28 days and included the assessment of mechanical thresholds at the
knee, weight bearing and locomotor coordination on a rotarod.
Results: Mechanical thresholds at the knee were signiﬁcantly decreased
in saline treated animals. However, a single IA injection of Durolane on
day 1 revealed similar anti-nociceptive effects as did the subcutaneous
injection of morphine on each testing day until the end of the observation
period at day 28. Signiﬁcant differences between saline and Durolane
were seen at days 1, 2, 4, 14 and 28. The incapacitance test showed
that animals treated with Durolane favoured a more 1:1 weight bearing
between treated and untreated limbs. This result was again similar to
those receiving a daily injection of morphine, whereas those treated
with saline favoured the untreated limb, i.e. protecting the injected limb.
Signiﬁcant differences were seen at days 1, 2 and 14 between the
saline and Durolane groups. Rotarod parameters indicating locomotive
function were not signiﬁcantly altered from baseline measures with any of
the treatments administered. This demonstrates that animals could walk
normally and that the pain inducing agents were not causing intolerable
pain in the joints.
Conclusions: This study has demonstrated that a single IA injection of
Durolane provides anti-nociceptive effects until at least day 28, in this
model of induced joint pain.
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Purpose: Joint disease and speciﬁcally osteoarthritis (OA) is one of the
most prevalent and debilitating diseases affecting horses and humans.
